Compare $ATNM vs $QNCX | Chartloom

Compare

$ATNM vs $QNCX

Actinium Pharmaceuticals Inc · Quince Therapeutics Inc

ATNM

Actinium Pharmaceuticals Inc

QNCX

Quince Therapeutics Inc

Compare $ATNM vs $QNCX

Comparing Actinium Pharmaceuticals Inc and Quince Therapeutics Inc

ATNMActinium Pharmaceuticals Inc

QNCXQuince Therapeutics Inc

ATNMActinium Pharmaceuticals Inc

Market cap

$35M

P/E (TTM)

3.06x

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-19.7%

52W performance

-28.6%

FCF yield

-67.4%

QNCXQuince Therapeutics Inc

Market cap

$31M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-94.7%

52W performance

-91.7%

FCF yield

-151.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ATNM

QNCX

Detailed metrics comparison

ATNM

Actinium Pharmaceuticals Inc

QNCX

Quince Therapeutics Inc

Market Cap

ATNM$35M

QNCX$31M

Enterprise Value

ATNM$-2M

QNCX$-85M

Price

ATNM$1.10

QNCX$31.73

P/E Ratio

ATNM3.06x

QNCXN/A

P/S Ratio

ATNM0.98x

QNCX0.00x

EV/Sales

ATNM-0.06x

QNCX0.00x

EV/EBITDA

ATNM-0.20x

QNCX0.00x

P/B Ratio

ATNM1.21x

QNCX0.27x

P/FCF Ratio

ATNMN/A

QNCXN/A

EV/FCF

ATNM0.08x

QNCX1.81x

PEG Ratio

ATNMN/A

QNCXN/A

Forward P/E (NTM)

ATNMN/A

QNCXN/A

Forward P/S (NTM)

ATNMN/A

QNCXN/A

Revenue (TTM)

ATNM$35M

QNCX$0

Revenue Growth (YoY)

ATNMN/A

QNCXN/A

Forward Rev Growth

ATNM-0.2%

QNCX114.8%

Gross Margin (TTM)

ATNM0.0%

QNCX0.0%

Operating Margin (TTM)

ATNM62.3%

QNCX0.0%

EBITDA Margin (TTM)

ATNM27.9%

QNCX0.0%

Net Margin (TTM)

ATNM32.2%

QNCX0.0%

FCF Margin (TTM)

ATNM-66.2%

QNCXN/A

Net Income (TTM)

ATNM$11M

QNCX$-92M

FCF (TTM)

ATNM$-23M

QNCX$-47M

EPS (TTM)

ATNM$0.36

QNCX-$15.08

ROE (TTM)

ATNM83.4%

QNCX-12702.0%

ROA (TTM)

ATNM23.4%

QNCX-10448.0%

ROIC (TTM)

ATNM83.4%

QNCX-11143.0%

Cash

ATNM$36M

QNCX$116M

Debt

ATNM$5K

QNCX$0

Net Cash/Debt

ATNM$36M

QNCX$116M

Current Ratio (TTM)

ATNM4.08x

QNCX14.52x

Quick Ratio (TTM)

ATNM3.94x

QNCX14.28x

Debt/Equity (TTM)

ATNM0.00x

QNCX0.48x

Debt/Assets (TTM)

ATNM0.0%

QNCX0.0%

Interest Coverage (TTM)

ATNMN/A

QNCXN/A

Net Debt/EBITDA (TTM)

ATNM0.00x

QNCX0.00x

Beta

ATNM0.33

QNCX1.80

52W Performance

ATNM-28.6%

QNCX-91.7%

YTD Performance

ATNM-19.7%

QNCX-94.7%

% from 52W High

ATNM-36.8%

QNCX-96.5%

% from 52W Low

ATNM49.6%

QNCX110.1%

Asset Turnover (TTM)

ATNM0.73x

QNCX0.00x

FCF Yield (TTM)

ATNM-67.4%

QNCX-151.2%

Earnings Yield (TTM)

ATNM32.8%

QNCX-297.4%

Dividend Yield (TTM)

ATNMN/A

QNCXN/A

Rule of 40

ATNM-66.2

QNCX0.0

EV/GP/RG

ATNMN/A

QNCXN/A

Ticker research

View ATNM research View QNCX research

Metric	ATNM Actinium Pharmaceuticals Inc	QNCX Quince Therapeutics Inc
Market & Valuation
Market Cap	$35M	$31M
Enterprise Value	$-2M	$-85M
Price	$1.10	$31.73
P/E Ratio	3.06x	N/A
P/S Ratio	0.98x	0.00x
EV/Sales	-0.06x	0.00x
EV/EBITDA	-0.20x	0.00x
P/B Ratio	1.21x	0.27x
P/FCF Ratio	N/A	N/A
EV/FCF	0.08x	1.81x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$35M	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	-0.2%	114.8%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	62.3%	0.0%
EBITDA Margin (TTM)	27.9%	0.0%
Net Margin (TTM)	32.2%	0.0%
FCF Margin (TTM)	-66.2%	N/A
Net Income (TTM)	$11M	$-92M
FCF (TTM)	$-23M	$-47M
EPS (TTM)	$0.36	-$15.08
ROE (TTM)	83.4%	-12702.0%
ROA (TTM)	23.4%	-10448.0%
ROIC (TTM)	83.4%	-11143.0%
Financial Health
Cash	$36M	$116M
Debt	$5K	$0
Net Cash/Debt	$36M	$116M
Current Ratio (TTM)	4.08x	14.52x
Quick Ratio (TTM)	3.94x	14.28x
Debt/Equity (TTM)	0.00x	0.48x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.33	1.80
52W Performance	-28.6%	-91.7%
YTD Performance	-19.7%	-94.7%
% from 52W High	-36.8%	-96.5%
% from 52W Low	49.6%	110.1%
Efficiency & Yields
Asset Turnover (TTM)	0.73x	0.00x
FCF Yield (TTM)	-67.4%	-151.2%
Earnings Yield (TTM)	32.8%	-297.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-66.2	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ATNM research	View QNCX research

Valuation

P/E Ratio

ATNM

3.06x

P/S Ratio

QNCX

0.00x

ATNM

0.98x

EV/FCF

ATNM

0.08x

QNCX

1.81x

Growth & revenue

Forward Revenue Growth

QNCX

114.8%

ATNM

-0.2%

Profitability & performance

Gross Margin

ATNM

0.0%

QNCX

0.0%

ROE

ATNM

83.4%

QNCX

-12702.0%

FCF Yield %

ATNM

-67.4%

QNCX

-151.2%

52-Week Performance

ATNM

-28.6%

QNCX

-91.7%

Detailed metrics comparison

ATNM

Actinium Pharmaceuticals Inc

QNCX

Quince Therapeutics Inc

Market Cap

ATNM$35M

QNCX$31M

Enterprise Value

ATNM$-2M

QNCX$-85M

Price

ATNM$1.10

QNCX$31.73

P/E Ratio

ATNM3.06x

QNCXN/A

P/S Ratio

ATNM0.98x

QNCX0.00x

EV/Sales

ATNM-0.06x

QNCX0.00x

EV/EBITDA

ATNM-0.20x

QNCX0.00x

P/B Ratio

ATNM1.21x

QNCX0.27x

P/FCF Ratio

ATNMN/A

QNCXN/A

EV/FCF

ATNM0.08x

QNCX1.81x

PEG Ratio

ATNMN/A

QNCXN/A

Forward P/E (NTM)

ATNMN/A

QNCXN/A

Forward P/S (NTM)

ATNMN/A

QNCXN/A

Revenue (TTM)

ATNM$35M

QNCX$0

Revenue Growth (YoY)

ATNMN/A

QNCXN/A

Forward Rev Growth

ATNM-0.2%

QNCX114.8%

Gross Margin (TTM)

ATNM0.0%

QNCX0.0%

Operating Margin (TTM)

ATNM62.3%

QNCX0.0%

EBITDA Margin (TTM)

ATNM27.9%

QNCX0.0%

Net Margin (TTM)

ATNM32.2%

QNCX0.0%

FCF Margin (TTM)

ATNM-66.2%

QNCXN/A

Net Income (TTM)

ATNM$11M

QNCX$-92M

FCF (TTM)

ATNM$-23M

QNCX$-47M

EPS (TTM)

ATNM$0.36

QNCX-$15.08

ROE (TTM)

ATNM83.4%

QNCX-12702.0%

ROA (TTM)

ATNM23.4%

QNCX-10448.0%

ROIC (TTM)

ATNM83.4%

QNCX-11143.0%

Cash

ATNM$36M

QNCX$116M

Debt

ATNM$5K

QNCX$0

Net Cash/Debt

ATNM$36M

QNCX$116M

Current Ratio (TTM)

ATNM4.08x

QNCX14.52x

Quick Ratio (TTM)

ATNM3.94x

QNCX14.28x

Debt/Equity (TTM)

ATNM0.00x

QNCX0.48x

Debt/Assets (TTM)

ATNM0.0%

QNCX0.0%

Interest Coverage (TTM)

ATNMN/A

QNCXN/A

Net Debt/EBITDA (TTM)

ATNM0.00x

QNCX0.00x

Beta

ATNM0.33

QNCX1.80

52W Performance

ATNM-28.6%

QNCX-91.7%

YTD Performance

ATNM-19.7%

QNCX-94.7%

% from 52W High

ATNM-36.8%

QNCX-96.5%

% from 52W Low

ATNM49.6%

QNCX110.1%

Asset Turnover (TTM)

ATNM0.73x

QNCX0.00x

FCF Yield (TTM)

ATNM-67.4%

QNCX-151.2%

Earnings Yield (TTM)

ATNM32.8%

QNCX-297.4%

Dividend Yield (TTM)

ATNMN/A

QNCXN/A

Rule of 40

ATNM-66.2

QNCX0.0

EV/GP/RG

ATNMN/A

QNCXN/A

Ticker research

View ATNM research View QNCX research

Metric	ATNM Actinium Pharmaceuticals Inc	QNCX Quince Therapeutics Inc
Market & Valuation
Market Cap	$35M	$31M
Enterprise Value	$-2M	$-85M
Price	$1.10	$31.73
P/E Ratio	3.06x	N/A
P/S Ratio	0.98x	0.00x
EV/Sales	-0.06x	0.00x
EV/EBITDA	-0.20x	0.00x
P/B Ratio	1.21x	0.27x
P/FCF Ratio	N/A	N/A
EV/FCF	0.08x	1.81x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$35M	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	-0.2%	114.8%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	62.3%	0.0%
EBITDA Margin (TTM)	27.9%	0.0%
Net Margin (TTM)	32.2%	0.0%
FCF Margin (TTM)	-66.2%	N/A
Net Income (TTM)	$11M	$-92M
FCF (TTM)	$-23M	$-47M
EPS (TTM)	$0.36	-$15.08
ROE (TTM)	83.4%	-12702.0%
ROA (TTM)	23.4%	-10448.0%
ROIC (TTM)	83.4%	-11143.0%
Financial Health
Cash	$36M	$116M
Debt	$5K	$0
Net Cash/Debt	$36M	$116M
Current Ratio (TTM)	4.08x	14.52x
Quick Ratio (TTM)	3.94x	14.28x
Debt/Equity (TTM)	0.00x	0.48x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.33	1.80
52W Performance	-28.6%	-91.7%
YTD Performance	-19.7%	-94.7%
% from 52W High	-36.8%	-96.5%
% from 52W Low	49.6%	110.1%
Efficiency & Yields
Asset Turnover (TTM)	0.73x	0.00x
FCF Yield (TTM)	-67.4%	-151.2%
Earnings Yield (TTM)	32.8%	-297.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-66.2	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ATNM research	View QNCX research